AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Files An 8-K Results of Operations and Financial Condition

AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02.

Results of Operations and Financial
Condition.

On March 9, 2017, Aevi Genomic Medicine, Inc., a Delaware
corporation (the Company), issued a press release regarding its
financial results for the three and twelve months ended December
31, 2016. A copy of this press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are furnished herewith:

Exhibit No. Description
99.1

Aevi Genomic Medicine, Inc. Press Release dated March 9,
2017 (furnished to Item 2.02).


About AEVI GENOMIC MEDICINE, INC. (LON:MEDG)

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company’s product candidates include AEVI-001 and AEVI-002. The Company’s research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children’s Hospital of Philadelphia (CHOP). .

AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Recent Trading Information

AEVI GENOMIC MEDICINE, INC. (LON:MEDG) closed its last trading session at 0.0000 with shares trading hands.

An ad to help with our costs